Literature DB >> 23756819

[MSA-QoL: disease-specific questionnaire to assess health-related quality of life in multiple system atrophy: validation of the German translation].

F Krismer1, S Duerr, M Minnerop, T Klockgether, M Stamelou, K M Eggert, W H Oertel, A Schrag, W Poewe, G K Wenning.   

Abstract

BACKGROUND: Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative disorder which causes early sustained disability and quality of life impairment. Recently, a self-reported questionnaire focusing on MSA-specific symptoms (Multiple System Atrophy Quality of Life questionnaire, MSA-QoL) was developed in the English language. This article reports the validation of the German translation of the MSA-QoL.
METHODS: Translation of the MSA-QoL was implemented in a 3-tiered approach including a forward translation, a back translation and an independent review. For the validation study 38 consecutive patients with MSA according to the consensus criteria were recruited by the participating centers in a German-Austrian cohort. Data were analyzed using standard psychometric procedures.
RESULTS: As determined by the independent review, the German translation of the MSA-QoL was classified as fully equivalent to the English version. The validation study confirmed good psychometric properties of the rating scale.
CONCLUSION: The German translation of the MSA-QoL was shown to be a reliable patient-reported rating scale to determine health-related quality of life in MSA patients.

Entities:  

Mesh:

Year:  2013        PMID: 23756819     DOI: 10.1007/s00115-013-3764-1

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  18 in total

1.  EuroQol--a new facility for the measurement of health-related quality of life.

Authors: 
Journal:  Health Policy       Date:  1990-12       Impact factor: 2.980

2.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

3.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

4.  Health-related quality of life in multiple system atrophy.

Authors:  Anette Schrag; Felix Geser; Michaela Stampfer-Kountchev; Klaus Seppi; Martin Sawires; Martin Köllensperger; Christoph Scherfler; Niall Quinn; Maria T Pellecchia; Paolo Barone; Francesca Del Sorbo; Alberto Albanese; Karen Ostergaard; Erik Dupont; Adriana Cardozo; Eduardo Tolosa; Christer F Nilsson; Håkan Widner; Olle Lindvall; Nir Giladi; Tanya Gurevich; Christine Daniels; Günther Deuschl; Miguel Coelho; Cristina Sampaio; Michael Abele; Thomas Klockgether; Nicole Schimke; Karla M Eggert; Wolfgang Oertel; Ruth Djaldetti; Carlo Colosimo; Giuseppe Meco; Werner Poewe; Gregor K Wenning
Journal:  Mov Disord       Date:  2006-06       Impact factor: 10.338

5.  Clinical features and natural history of multiple system atrophy. An analysis of 100 cases.

Authors:  G K Wenning; Y Ben Shlomo; M Magalhães; S E Daniel; N P Quinn
Journal:  Brain       Date:  1994-08       Impact factor: 13.501

6.  Clinical outcomes of progressive supranuclear palsy and multiple system atrophy.

Authors:  S S O'Sullivan; L A Massey; D R Williams; L Silveira-Moriyama; P A Kempster; J L Holton; T Revesz; A J Lees
Journal:  Brain       Date:  2008-04-02       Impact factor: 13.501

7.  Measuring health-related quality of life in MSA: the MSA-QoL.

Authors:  Anette Schrag; Caroline Selai; Chris Mathias; Philip Low; Jeremy Hobart; Niall Brady; Niall Patrick Quinn
Journal:  Mov Disord       Date:  2007-12       Impact factor: 10.338

8.  Survival in multiple system atrophy.

Authors:  Anette Schrag; Gregor K Wenning; Niall Quinn; Yoav Ben-Shlomo
Journal:  Mov Disord       Date:  2008-01-30       Impact factor: 10.338

9.  Second consensus statement on the diagnosis of multiple system atrophy.

Authors:  S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet
Journal:  Neurology       Date:  2008-08-26       Impact factor: 9.910

10.  Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.

Authors:  Gilbert Bensimon; Albert Ludolph; Yves Agid; Marie Vidailhet; Christine Payan; P Nigel Leigh
Journal:  Brain       Date:  2008-11-23       Impact factor: 13.501

View more
  1 in total

1.  Clinical assessment of dysphagia in neurodegeneration (CADN): development, validity and reliability of a bedside tool for dysphagia assessment.

Authors:  Adam P Vogel; Natalie Rommel; Carina Sauer; Marius Horger; Patrick Krumm; Marc Himmelbach; Matthis Synofzik
Journal:  J Neurol       Date:  2017-05-03       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.